Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
2 way Dual Activation GHRH-R (CJC-1295) + GHS-R1a (Ipamorelin) two complementary pituitary targets 2-4x GH AUC Demonstrated Synergy Area under the GH curve 2 to 4 times greater than each peptide in monotherapy 5.8 - 8.1 days CJC-1295 Half-Life Sustained elevation of IGF-1 for 9 to 11 days after a single injection 10 mg Pre-formulated mix 5 mg CJC-1295 (No DAC) + 5 mg Ipamorelin per vial | Purity 99% HPLC Selective Hormonal Profile Ipamorelin: no increase in cortisol, prolactin or ACTH (Raun et al., 1998) Mechanism of Action Dual-Channel Synergy Simultaneous activation of GHRH-R and GHS-R1a for amplified GH stimulation GHRH Lane CJC-1295 GHRH Analog (Mod GRF 1-29) A synthetic peptide of 29 amino acids that selectively binds to the GHRH receptor on pituitary somatotroph cells
Bupropion also may reduce large fluctuations in dopamine, especially when associated with food or eating, he says
Paller A, Butala S, Howe, W
Others discover that they cannot reduce below a certain threshold without weight creeping back
Content Lose some, win some Reviewed by Craig Primack, MD, FACP, FAAP, FOMA Written by Vanessa Gibbs Published 05/31/2025 Nausea and GLP-1 receptor agonists (thats glucagon-like peptide 1 receptor agonists) often go hand in hand
The observed neuroprotective effects of GLP-1R agonists can be attributed to a possible mechanistic link between Parkinsons disease and diabetes
US$ 24.15
US$ 22.92
US$ 24.56
US$ 25.57
